Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.
about
Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration.Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.Recombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in mice.Feasibility study of lamellar keratoplasty in a murine model.A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration.Complement regulatory protein CD46 protects against choroidal neovascularization in mice.A caveat for T cell transfer studies: generation of cytotoxic anti-Thy1.2 antibodies in Thy1.1 congenic mice given Thy1.2+ tumors or T cellsGalectin-9-mediated protection from allo-specific T cells as a mechanism of immune privilege of corneal allografts.Adeno-associated virus mediated delivery of a non-membrane targeted human soluble CD59 attenuates some aspects of diabetic retinopathy in mice.Differential Effects of C1qa Ablation on Glaucomatous Damage in Two Sexes in DBA/2NNia Mice.The role of complement system in ocular diseases including uveitis and macular degeneration.The role of complement in ocular pathology.Role of NKT cells in anterior chamber-associated immune deviationImmune escape mechanisms of intraocular tumors.Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantationRetinal changes precede visual dysfunction in the complement factor H knockout mouse.Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT.Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism?
P2860
Q31131792-ADB8E457-FC4E-4968-B258-671C46B1D61CQ33397385-564F0B64-CE14-41A2-885D-BEC6F362E003Q33671677-9294A220-FE03-4746-ACAE-A7ED8B86B49FQ33724962-8054DAF8-3A86-4881-A33D-06BAF2F7D385Q33892696-6153C49E-780D-4669-B3C4-E2614659A196Q34299745-2D0ADAA0-920E-479D-9459-BC8277C3D032Q34510107-0ED01318-741D-4626-A97D-6452DD2DB681Q34718313-D2799FAD-4C50-422E-BC3E-CC8942A3CACBQ35027989-97533431-C6D2-4C7E-B056-362D2FC4EFD9Q36257964-68137296-7105-4611-9255-D78131A78A36Q36927874-E9F2064C-4111-44E2-A486-2F2FA12410CAQ37094617-90976B91-3A47-49A4-8403-ABAF2E20D165Q37280696-57488F26-553C-4F3E-BC87-127209C02CCEQ37535138-BEF954B4-7FD8-4282-AC2B-C7673AD7CDD3Q37674078-C9580253-7C9D-4CAA-9F25-F702B3628090Q41295415-FC3143AF-0B63-4FDD-B4B8-08B63B752355Q41921240-E7140558-460B-48EF-9081-FCBDD82353EFQ42200330-E2E6C4C5-239C-418F-921D-4197211EFF55
P2860
Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Complement regulatory activity ...... ediated by MCP, DAF, and CD59.
@ast
Complement regulatory activity ...... ediated by MCP, DAF, and CD59.
@en
type
label
Complement regulatory activity ...... ediated by MCP, DAF, and CD59.
@ast
Complement regulatory activity ...... ediated by MCP, DAF, and CD59.
@en
prefLabel
Complement regulatory activity ...... ediated by MCP, DAF, and CD59.
@ast
Complement regulatory activity ...... ediated by MCP, DAF, and CD59.
@en
P2093
P2860
P1476
Complement regulatory activity ...... mediated by MCP, DAF, and CD59
@en
P2093
P2860
P304
P407
P577
2000-12-01T00:00:00Z